Danaparoid—Consensus Recommendations on Its Clinical Use

(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology...

詳細記述

書誌詳細

主要な著者:	Rupert M. Bauersachs, Edelgard Lindhoff-Last, Robert Klamroth, Andreas Koster, Marc Schindewolf, Harry Magnani
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2024-11-01
シリーズ:	Pharmaceuticals
主題:	Orgaran danaparoid heparinoid anticoagulant dosing monitoring
オンライン･アクセス:	https://www.mdpi.com/1424-8247/17/12/1584
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!